FDA creates 'Bad Ad' program

The Food and Drug Administration (FDA) launched the "Bad Ad" program, a new effort that aims to encourage physicians to identify and report misleading drug advertising and marketing.

The Food and Drug Administration (FDA) launched the "Bad Ad" program, a new effort that aims to encourage physicians to identify and report misleading drug advertising and marketing.

Until the program launched this week, the federal agency had several dozen staffers who reviewed ads, brochures, and presentations that are voluntarily submitted by companies. To raise awareness about the program, the FDA plans to attend medical conferences and sent a letter to 33,000 healthcare providers about "Bad Ad."

BNET's Jim Edwards writes that the program "is the latest example of the FDA's renewed activism under President Obama. FDA warning letters — which cite drug companies for misleading advertising or bad manufacturing practices — have increased 31 percent since 2008, and 50 percent since 2007."

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in